Generic Lopinavir & Ritonavir Tablets

Ritoheet-L (Lopinavir and Ritonavir Tablets) - Product Information

Ritoheet-L (Lopinavir and Ritonavir tablets) is an HIV-1 protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients.

Ritoheet-L tablets, are manufactured by Mcneil & Argus Pharmaceuticals Limited, India in the strengths of 250 mg (200 mg of Lopinavir and 50 mg of Ritonavir). The price of one 250 mg tablet is only $1.58. This the cheapest price of generic Lopinavir and Ritonavir tablets without insurance.
We also have in stock Generic Atazanavir (Atavir Capsules) which is also used in combination with other medicines to treat the same indications.

Name of the Drug

We supply original Ritoheet-L tablets manufactured by Mcneil & Argus Pharmaceuticals Limited.

Manufacturer of Ritoheet-L Tablets

Mcneil & Argus Pharmaceuticals Limited, India  
Website: mcneilargusindia.com

Active Ingredient present in Ritoheet-L Tablets

The active ingredients present in Ritoheet-L tablets are Lopinavir and Ritonavir. Each film-coated tablet Ritoheet-L of contains 200 mg of Lopinavir and 50 mg of Ritonavir.

Uses of Ritoheet-L (Generic Lopinavir and Ritonavir Tablets)

Ritoheet-L (Generic Lopinavir and Ritonavir Tablets) is used in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years.
The choice of Ritoheet-L to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.

The combination of Lopinavir and Ritonavir (Ritoheet-L tablets) has also been used for Coronavirus (Covid-19) treatment.

Ritoheet-L (Generic Lopinavir and Ritonavir Tablets) - Dosage

Ritoheet-L tablets can be taken with or without food. Ritoheet-L tablets should be swallowed whole. Do not chew, break or crush Ritoheet-L tablets. The dose of Ritoheet-L tablets is as follows:
Adults:
Total recommended daily dosage is 800/200 mg (given as four 200/50 mg tablets) given once or twice daily. Ritoheet-L can be given as once daily or twice daily regimen.
Ritoheet-L (Generic Lopinavir and Ritonavir Tablets) once daily dosing regimen is not recommended in:

• Adult patients with three or more of the following Lopinavir resistance-associated substitutions: L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V.
• In combination with Carbamazepine, Phenobarbital, Or Phenytoin.
• In combination with Efavirenz, Nevirapine, or Nelfinavir.
• In pregnant women.

Concomitant Therapy in Adults:
Dose adjustments of Ritoheet-L may be needed when co-administering with Efavirenz, Nevirapine, or Nelfinavir.
Pregnancy:

• 400/100 mg twice daily in pregnant patients with no documented Lopinavir ­associated resistance substitutions.
• There are insufficient data to recommend a Ritoheet-L dose for pregnant patients with any documented Ritoheet-L associated resistance substitutions.
• No dose adjustment of Ritoheet-L is required for patients during the postpartum period.

Ritoheet-L (Generic Lopinavir and Ritonavir Tablets) Storage

Store Ritoheet-L (Generic Lopinavir and Ritonavir Tablets) at controlled room temperature (59°F to 86°F, 15°C to 30°C). Protect from light.

Ritoheet-L Contraindications

Ritoheet-L tablets are contraindicated in patients with a hypersensitivity (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, urticaria, angioedema) to Lopinavir, Ritonavir or any inactive ingredient present in tablets. Ritoheet-L are contraindicated in the following cases:

• Co-administration with drugs highly dependent on CYP3A for clearance and for which elevated plasma levels may result in serious and/or life-threatening events.
• Co-administration with potent CYP3A inducers where significantly reduced lopinavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance and cross resistance.

Warnings and Precautions

The following have been observed in patients receiving Ritoheet-L (Generic Lopinavir and Ritonavir Tablets):

• The concomitant use of Ritoheet-L and certain other medicines may result in known or potentially significant drug interactions.
• Toxicity in preterm neonates: Lopinavir and Ritonavir oral solution should not be used in preterm neonates in the immediate postnatal period because of possible toxicities. A safe and effective dose of Lopinavir and Ritonavir oral solution in this patient population has not been established.
• Pancreatitis:Fatalities have occurred; suspend therapy as clinically appropriate.
• Hepatotoxicity: Fatalities have occurred. Monitor liver function before and during therapy, especially in patients with underlying hepatic disease, including hepatitis B and hepatitis C, or marked transaminase elevations.
• QT interval prolongation and isolated cases of torsade depointes have been reported although causality could not be established. Avoid use in patients with congenital long QT syndrome, those with hypokalemia, and with other drugs that prolong the QT interval.
• PR interval prolongation may occur in some patients. Cases of second and third degree heart block have been reported. Use with caution in patients with pre-existing conduction system disease, ischemic heart disease, cardiomyopathy, underlying structural heart disease or when administering with other drugs that may prolong the PR interval.
• Patients may develop new onset or exacerbations of diabetes mellitus, hyperglycemia, immune reconstitution syndrome, redistribution/accumulation of body fat.
• Total cholesterol and triglycerides elevations. Monitor prior to therapy and periodically thereafter.
• Hemophilia: Spontaneous bleeding may occur, and additional factor VIII may be required

Ritoheet-L (Lopinavir and Ritonavir Tablets) Side Effects

The most common Ritoheet-L (Lopinavir and Ritonavir tablets) side effects occurring in 5% or more of the patients undergoing treatment with this medication were diarrhea, nausea, abdominal pain, asthenia, vomiting, headache, and dyspepsia.

The most commonly reported Generic Lopinavir and Ritonavir tablets side effects of moderate severity that are thought to be drug related are: abdominal pain, abnormal stools (bowel movements), diarrhea, feeling tired, headache, and nausea. Children taking this medicine may sometimes get a skin rash.

Blood tests in patients taking this medicine may show possible liver problems. People with liver disease such as Hepatitis B and Hepatitis C who take this medicine may have worsening liver disease. Liver problems including death have occurred in patients taking this medicine. In studies, it is unclear if this medicine caused these liver problems because some patients had other illnesses or were taking other medicines.

Some patients taking this medicine can develop serious problems with their pancreas (pancreatitis), which may cause death. You have a higher chance of having pancreatitis if you have had it before. Tell your doctor if you have nausea, vomiting, or abdominal pain. These may be signs of pancreatitis.

Some patients have large increases in triglycerides and cholesterol. The long-term chance of getting complications such as heart attacks or stroke due to increases in triglycerides and cholesterol caused by protease inhibitors is not known at this time.

Diabetes and high blood sugar (hyperglycemia) occur in patients taking protease inhibitors such as this medicine. Some patients had diabetes before starting protease inhibitors, others did not. Some patients need changes in their diabetes medicine. Others needed new diabetes medicine.

Changes in body fat have been seen in some patients taking antiretroviral therapy. These changes may include increased amount of fat in the upper back and neck ("buffalo hump"), breast, and around the trunk. Loss of fat from the legs, arms and face may also happen. The cause and long term health effects of these conditions are not known at this time.

Some patients with hemophilia have increased bleeding with protease inhibitors. There have been other side effects in patients taking this medicine. However, these side effects could have been due to other medicines that patients were taking or to the illness itself. Some of these side effects can be serious.

Lopinavir and Ritonavir Tablets (Ritoheet-L) Overdosage

To date, there is limited human experience of acute overdose with Lopinavir and Ritonavir tablets (Ritoheet-L).
The adverse clinical signs observed in dogs included salivation, emesis and diarrhoea/abnormal stool. The signs of toxicity observed in mice, rats or dogs included decreased activity, ataxia, emaciation, dehydration and tremors.

There is no specific antidote for overdose with Ritoheet-L. Treatment of overdose with Ritoheet-L is to consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. If indicated, elimination of unabsorbed active substance is to be achieved by emesis or gastric lavage.
Administration of activated charcoal may also be used to aid in removal of unabsorbed active substance. Since Ritoheet-L is highly protein bound, dialysis is unlikely to be beneficial in significant removal of the active substance.

Lopinavir and Ritonavir Tablets (Ritoheet-L) During Pregnancy

Lopinavir and Ritonavir tablets (Ritoheet-L) has been classified by the US FDA as Pregnancy Category C. Data from the Antiretroviral Pregnancy Registry shows no difference in the risk of overall major birth defects compared to the background rate for major birth defects.

No treatment-related malformations were noticed when Lopinavir in combination with Ritonavir was administered to pregnant rats or rabbits. However embryonic and fetal developmental toxicities occurred in rats administered maternally toxic doses. There are insufficient data to recommend Ritoheet-L dosing for pregnant patients with any documented Lopinavir-associated resistance substitutions. No dose adjustment of Ritoheet-L is required for patients during the postpartum period. Once daily Ritoheet-L dosing is not recommended in pregnancy. Do not use Generic Lopinavir and Ritonavir Tablets (Ritoheet-L) without your doctor's consent in case you are pregnant.

Lopinavir and Ritonavir Tablets (Ritoheet-L) Nursing Considerations

HIV-infected mothers should not breast-feed their infants to avoid risking postnatal transmission of HIV. It is not known whether Lopinavir or Ritonavir is present in human milk.

Due to the fact that the potential for HIV transmission exists as well as the potential for serious adverse reactions in nursing infants, mothers should be instructed not to breast-feed if they are taking Generic Lopinavir and Ritonavir Tablets (Ritoheet-L tablets).

Buy Generic Lopinavir and Ritonavir Tablets (Ritoheet-L) Pills Online at Only $1.58 per Pill

You can buy Generic Lopinavir and Ritonavir Tablets (Ritoheet-L) online from Clear Sky Pharmacy at a cheap price. Ritoheet-L 250 mg (200 mg of Lopinavir and 50 mg of Ritonavir) pills, manufactured by Mcneil & Argus Pharmaceuticals Limited, India are supplied in a blister strip of 10 tablets. The 250 mg tablets cost only $1.58 per unit when you place an order for 360 tablets.

Disclaimer

The above information is provided to the best of our knowledge and in good faith, it is without a warrant of any kind, expressed or implied.

Shipping Restriction